Core Insights - Autonomix Medical, Inc. has advanced its proprietary sensing catheter through a final design review, preparing for human clinical trials aimed at supporting a De Novo FDA application [1][3] - The innovative sensing catheter is the first intravascular device designed to detect and differentiate nerve signals in real time, enhancing treatment precision and reducing the risks of incomplete denervation or overtreatment [2][3] - The technology has the potential to transform neuromodulation and pain treatment, with applications across various therapeutic areas including cardiology, hypertension, and chronic pain management [3][6] Company Overview - Autonomix Medical, Inc. focuses on advancing innovative technologies for diagnosing and treating diseases involving the nervous system, utilizing a catheter-based microchip sensing array [5][6] - The company is initially developing its technology for treating pain associated with pancreatic cancer, a condition that currently lacks reliable treatment options [6] Development Milestones - The company is executing an operational plan to submit an Investigational Device Exemption (IDE) and commence U.S. clinical trials for the Autonomix Sensing and RF Ablation System, specifically targeting pancreatic cancer pain [4][6] - Completion of the design review milestone is seen as a significant step towards delivering safer and more effective treatment options for patients, while also creating value for shareholders [3]

Core Viewpoint - Autonomix Medical, Inc. has received a significant patent that enhances its position in the nerve-focused therapeutics market, supporting its mission to provide minimally invasive treatments for various nerve-related conditions [1][2]. Group 1: Patent and Technology - The newly issued U.S. Patent No. 12,279,889 B2 ('889 patent) relates to advanced systems for evaluating and modifying neurological functions, including tools for accessing small vessels and treating cancerous tumors [1][3]. - The technology includes integrated sensors in microneedles for deep tissue access, multiband optical sensors for tissue viability, and control systems that adjust treatment based on feedback signals [3][4]. - Autonomix's platform utilizes a catheter-based microchip sensing array that can detect neural signals with greater sensitivity than existing technologies, enabling a precision-guided approach to treat chronic pain and other conditions [4][6]. Group 2: Market Opportunity and Clinical Trials - The patent strengthens Autonomix's intellectual property portfolio, which now includes over 80 issued patents, positioning the company in a multi-billion-dollar market opportunity [1][2]. - The company plans to submit an Investigational Device Exemption (IDE) and begin U.S. clinical trials in 2025 for its Sensing and RF Ablation System, targeting pancreatic cancer pain [5][7]. - The technology aims to address a wide range of conditions influenced by sympathetic nerve activity, including hypertension and chronic pain syndromes, with the potential for numerous applications across various medical fields [1][7].

Core Viewpoint - Autonomix Medical, Inc. has strengthened its intellectual property position in the nerve-mapping and denervation space with the issuance of U.S. Patent No. 12,257,071, which supports its mission to advance minimally invasive, nerve-focused therapeutics [1][2]. Patent and Technology - The newly issued '071 patent relates to advanced catheter-based systems that combine nerve mapping and radiofrequency (RF) ablation technologies, enhancing precision in treating nerve-related conditions [1][3]. - Key features of the '071 patent include deployable microfingers with embedded sensors for real-time physiological monitoring, the ability to map, stimulate, ablate, and assess nerve activity in a single integrated system, and feedback-driven control of multiple types of procedures [3][4]. - The technology is designed to treat conditions influenced by sympathetic nerve activity, including renal denervation for hypertension, chronic pain syndromes, and various metabolic and neurological disorders [3][4]. Clinical Development and Future Plans - The company plans to submit an Investigational Device Exemption (IDE) and commence U.S. clinical trials in 2025 to support commercialization of the Autonomix Sensing and RF Ablation System as a treatment for pancreatic cancer pain [5][7]. - Autonomix's technology platform aims to revolutionize the diagnosis and treatment of diseases involving the nervous system, with initial trials focused on pancreatic cancer, a condition that causes debilitating pain [6][7]. Market Position and Strategy - The issuance of the patent marks a key milestone in the company's strategy to transform pain management and treat neurological disorders through minimally invasive, catheter-based denervation [2][4]. - The company currently holds over 80 issued patents and 40 pending patent applications, indicating a strong and expanding global patent portfolio [1][2].

New patent underscores breadth of application and expansion opportunities for Company's catheter-based technology Continued progress with growing global patent portfolio to over 80 issued patents and 40 pending patent applications THE WOODLANDS, TX, April 16, 2025 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ:AMIX) ("Autonomix" or the "Company"), a medical device company focused on advancing innovative technologies to revolutionize how diseases involving the nervous system are diagnosed and treated, t ...